Recce Pharmaceuticals Ltd. announced it completed dosing the first healthy subjects at the higher concentration of 3,000mg within a fast infusion rate of 15-minutes in a Phase I/II trial evaluating its lead anti-infective candidate, RECCE® 327 (R327). An independent safety committee recently unanimously concluded that R327 is safe and well tolerated in healthy male and female subjects at an infusion rate of 3,000mg via intravenous administration over 30 minutes. Since the previous cohort dosed, the committee approved a faster infusion rate, double that of what was previously delivered at 30 minutes, now being delivered at 3,000mg over 15 minutes.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.66 AUD | 0.00% | +1.54% | +23.36% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+23.36% | 87.41M | |
+32.97% | 704B | |
+28.09% | 577B | |
-4.57% | 348B | |
+18.29% | 327B | |
+4.61% | 288B | |
+14.64% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.76% | 147B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis